294 related articles for article (PubMed ID: 16259772)
1. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis.
Don BR; Spin G; Nestorov I; Hutmacher M; Rose A; Kaysen GA
J Pharm Pharmacol; 2005 Nov; 57(11):1407-13. PubMed ID: 16259772
[TBL] [Abstract][Full Text] [Related]
2. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.
Nestorov I; Zitnik R; DeVries T; Nakanishi AM; Wang A; Banfield C
Br J Clin Pharmacol; 2006 Oct; 62(4):435-45. PubMed ID: 16995864
[TBL] [Abstract][Full Text] [Related]
4. Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin.
Goldstein SL; Leung JC; Silverstein DM
Clin J Am Soc Nephrol; 2006 Sep; 1(5):979-86. PubMed ID: 17699316
[TBL] [Abstract][Full Text] [Related]
5. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels.
Borazan A; Ustün H; Ustundag Y; Aydemir S; Bayraktaroglu T; Sert M; Yilmaz A
Mediators Inflamm; 2004 Jun; 13(3):201-4. PubMed ID: 15223612
[TBL] [Abstract][Full Text] [Related]
6. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
Elewski B; Leonardi C; Gottlieb AB; Strober BE; Simiens MA; Dunn M; Jahreis A
Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
[TBL] [Abstract][Full Text] [Related]
7. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines.
Tarakçioğlu M; Erbağci AB; Usalan C; Deveci R; Kocabaş R
Mediators Inflamm; 2003 Feb; 12(1):15-9. PubMed ID: 12745544
[TBL] [Abstract][Full Text] [Related]
8. TNF-alpha: mRNA, plasma protein levels and soluble receptors in patients on chronic hemodialysis, on CAPD and with end-stage renal failure.
van Riemsdijk-van Overbeeke IC; Baan CC; Hesse CJ; Loonen EH; Niesters HG; Zietse R; Weimar W
Clin Nephrol; 2000 Feb; 53(2):115-23. PubMed ID: 10711413
[TBL] [Abstract][Full Text] [Related]
9. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A.
Nowlan ML; Drewe E; Bulsara H; Esposito N; Robins RA; Tighe PJ; Powell RJ; Todd I
Rheumatology (Oxford); 2006 Jan; 45(1):31-7. PubMed ID: 16287931
[TBL] [Abstract][Full Text] [Related]
10. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
11. On-line hemodiafiltration does not induce inflammatory response in end-stage renal disease patients: results from a multicenter cross-over study.
Vaslaki LR; Berta K; Major L; Weber V; Weber C; Wojke R; Passlick-Deetjen J; Falkenhagen D
Artif Organs; 2005 May; 29(5):406-12. PubMed ID: 15854217
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory status in patients with chronic renal failure: the role of PTX3 and pro-inflammatory cytokines.
Malaponte G; Libra M; Bevelacqua Y; Merito P; Fatuzzo P; Rapisarda F; Cristina M; Naselli G; Stivala F; Mazzarino MC; Castellino P
Int J Mol Med; 2007 Oct; 20(4):471-81. PubMed ID: 17786277
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis.
Yim DS; Zhou H; Buckwalter M; Nestorov I; Peck CC; Lee H
J Clin Pharmacol; 2005 Mar; 45(3):246-56. PubMed ID: 15703360
[TBL] [Abstract][Full Text] [Related]
16. Type 2 diabetes in patients with end-stage renal disease is not associated with further increased serum inflammatory parameters.
Bodlaj G; Berg J; Pichler R; Sailer T; Biesenbach G
J Nephrol; 2004; 17(1):112-7. PubMed ID: 15151267
[TBL] [Abstract][Full Text] [Related]
17. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation.
Fiaccadori E; Maggiore U; Rotelli C; Giacosa R; Parenti E; Picetti E; Manini P; Andreoli R; Cabassi A
Nephrol Dial Transplant; 2006 May; 21(5):1402-6. PubMed ID: 16504979
[TBL] [Abstract][Full Text] [Related]
18. Association of environmental cadmium exposure with inflammation and malnutrition in maintenance haemodialysis patients.
Hsu CW; Lin JL; Lin-Tan DT; Yen TH; Huang WH; Ho TC; Huang YL; Yeh LM; Huang LM
Nephrol Dial Transplant; 2009 Apr; 24(4):1282-8. PubMed ID: 19028751
[TBL] [Abstract][Full Text] [Related]
19. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.
Madhusudan S; Muthuramalingam SR; Braybrooke JP; Wilner S; Kaur K; Han C; Hoare S; Balkwill F; Ganesan TS
J Clin Oncol; 2005 Sep; 23(25):5950-9. PubMed ID: 16135466
[TBL] [Abstract][Full Text] [Related]
20. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.
Panichi V; Rizza GM; Paoletti S; Bigazzi R; Aloisi M; Barsotti G; Rindi P; Donati G; Antonelli A; Panicucci E; Tripepi G; Tetta C; Palla R;
Nephrol Dial Transplant; 2008 Jul; 23(7):2337-43. PubMed ID: 18305316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
